

IBI Services

Complete protein analysis

for drug development, treatment response, and diagnostics

PROTEOMICS BIOREACTIVE PROBE THERAPEUTICS
BIOMARKER PROTEOMICS ASSAY AUTISM DRUGS
CARDIAC DISEASE CANCER BIOMARKER DISCOVERY
MASS SPECTROMETRY MSIA-TIP ALZHEIMER'S PROTEIN

BIOMARKER
SPECTROSCOPY
MEDICINE
PROTEOMICS
CANCER
DISEASE CA
ETIOLOGY A



INTRINSIC BIOPROBES, INC.




Fueling innovation through protein analysis

High-throughput protein analysis can radically reduce the cycle time and cost of biomarker discovery, drug development, and disease diagnostics. Intrinsic Bioprobes, Inc. offers superior industrial-scale protein analysis services for investigating any protein detectable in human biological fluids. IBI can help your organization reveal protein variants related to specific diseases or that may be created during the administration of drugs. IBI applies its unparalleled expertise in human protein analysis through proven, cost-effective, proprietary tools and processes.

Advances in biomarker discovery

Nearly all biological events are enabled by or produce proteins. This makes information about proteins the best indication of many physiological and pathological states that identify diseases and other conditions. IBI's analysis services can identify specific changes in the protein composition of human bodily fluids, producing novel biomarkers that accelerate drug discovery and other research efforts.

IBI offers rapid, complete, qualitative and quantitative protein analysis. Our screening methods detect peptides of molecular weights of less than 1 kDa up to proteins of 300 kDa from sample volumes ranging from 1 microliter to 10 milliliters. IBI's characterization techniques detect proteins based on exact molecular weights, enabling analysis of dozens of proteins in a single assay. Regardless of your biological media, sample volume, or research interest, IBI can produce the data you need quickly, in high volume.





Effective diagnostics

Protein biomarkers help researchers monitor patients during pre-clinical and clinical drug development studies. Identifying responders and non-responders to experimental therapies allow researchers to focus on patients most likely to benefit. The safety and efficacy of therapeutics can be assessed sooner, thereby increasing the overall success rate of drug development. Fully automated processes for high sample throughput make it possible to assess increasingly granular patient subgroups. This enables your organization to bring better, individualized therapies to market faster, and more reliably.

Clinical response assessment

IBI offers cost-effective, high-throughput diagnostic services for disease screening, diagnosis, prognosis, therapy selection, and monitoring treatment. IBI can identify existing biomarkers in biological samples for patients suspected of having, or being susceptible to a given condition. IBI's methods are extremely sensitive, measuring the presence and functional state of proteins from very small sample quantities. Unlike tests for antibodies or genetic markers, specific proteins are highly accurate and sensitive markers for disease at very early stages of onset, making them ideal for diagnostic applications.



Optimized for commercial services

IBI has proprietary tools and techniques that optimize matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF/MS) for industrial operation. This integrated system handles all aspects of protein isolation and analysis directly from bodily fluids. Even when combined, other stand-alone robotic and MS systems capable of high-throughput, semi-automated analysis lack IBI's proprietary technologies (MSIA-Tips™ and BRP™) that enable specific tasks like recombinant protein analysis, biomolecular quantification, high-throughput ligand fishing, protein phenotyping, splice variant analysis, and more. Moreover, as IBI's approaches extract proteins directly from biological media, sample losses are kept to a minimum, and multiple, subsequent tests can be performed upon individual samples.

Partial Client List:

Analysis Services

Bayer, Pharmaceutical Division
R. W. Johnson Pharmaceutical Research Institute
Millenium Pharmaceuticals, Inc.
Dupont
Merck
Wyeth-Ayerst Research
Monsanto Corporation
Glaxo-Wellcome
Genencor, Inc.
NIH-NICHD

Research and Development

Arizonal Disease Control Research Commission
Biacore, AB (Upsala, Sweden)
Sequel Genetics
Phylomed Corporation

Contact IBI to accelerate your biomarker discovery or drug development research efforts, or to increase the sensitivity and cost-effectiveness of your clinical diagnostics. Our team will work with you to learn more about your organization's needs and tailor a solution that helps you get better results, faster.



INTRINSIC BIOPROBES, INC.

Intrinsic Bioprobes, Inc.
625 South Smith Road
Suite 22
Tempe, AZ 85281
www.intrinsicbio.com
info@intrinsicbio.com
Tel: 480-804-1778
Fax: 480-804-0778